** Cuban Doctors in Venezuela Only Allowed to Treat

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
294
** Cuban Doctors in Venezuela Only Allowed
to Treat Patients Who Support Maduro < >

Cuban doctors working in the crisis-stricken country of Venezuela have revealed that the socialist regime told them they must only provide essential medical treatments to those supporting the sham election campaign of dictator Nicolás Maduro.

According to a report in the New York Times, which has repeatedly taken money from the Maduro regime in exchange for publishing anti-American advertisements, 16 doctors involved in Cuba’s medical missions in the country were told they must deny treatments to those opposing the regime and go door-to-door in impoverished neighborhoods and offer treatment to those who still support the socialist revolution.

One doctor detailed how he was warned not to treat a 65-year-old patient in need of emergency care for his heart failure because the required oxygen tanks had to be preserved for guaranteeing the support of potential voters in last May’s sham presidential election, where opposition candidates were banned from participating.
Breitbart TV
Video Player is loading.
Venezuela Envoy Elliott Abrams: Maduro Supporters Who Violate Human Rights 'Not Welcome' In U.S.
Up Next
New Zealand Gun Shop Owner Who Sold Firearms to Terror Attack Suspect Supports New Call For Gun Law Reforms

“I asked myself, ‘Why is a physician, someone who is meant to be on a humanitarian mission, having a part in who wins an election?’” said one doctor on the condition of anonymity. “This is called tampering. There is no other word for it.”

Another doctor, dental surgeon Dr. Carlos Ramírez, spoke of how they were left disgusted by such an obvious violation of the Hippocratic Oath.

“You arrived with vitamins and some pills for blood pressure,” said Ramírez, who has since defected to Ecuador. “And when you started to gain their trust, you started the questions: ‘Do you know where your voting place is? Are you going to vote?’”

Many Cuban doctors work in Venezuela as part of an agreement between the two regimes. Venezuela typically pays for the doctors in vast quantities of oil, an initiative that began under Hugo Chávez and Fidel Castro and still continues to this day.

“With [late President Hugo] Chavez it had been hard, but with Maduro, starting in 2013, it was worse,” another Cuban doctor told the Times. “It became a form of blackmail: ‘You’re not going to have medicine. You’re not going to have free health care. You’re not going to have prenatal care if you’re a pregnant woman.’ ”

Medical internationalism has also been a key aspect of the Cuba foreign policy, with the regime sending around 52,000 medical workers in humanitarian missions to over 90 countries. Yet Cuban doctors have long complained that their work is effectively a form of slavery that forces them to earn negligible salaries as Cuban communist regime pockets a majority of profits.

According to a lawsuit filed by dozens of Cuban doctor in Brazil last year, benefitting countries pay Havana directly for the medical services while the doctors are provided with a stipend that barely covers living expenses.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading